These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28807142)

  • 1. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
    Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
    Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
    Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
    J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
    Mosolov SN; Malyutin AV; Pikalov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(12):29-37. PubMed ID: 31994511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
    Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A
    J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
    Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
    Feng Y; Shi J; Wang L; Zhang X; Tan Y; Zhao J; Ning Y; Xie S; Liu X; Liu Q; Li K; Wang X; Li L; Xu X; Deng W; Luo X; Wang G
    Psychiatry Clin Neurosci; 2020 Jun; 74(6):336-343. PubMed ID: 31823444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.
    Loebel A; Citrome L; Correll CU; Xu J; Cucchiaro J; Kane JM
    BMC Psychiatry; 2015 Oct; 15():271. PubMed ID: 26521019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
    J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.
    Costamagna I; Calisti F; Cattaneo A; Hsu J; Tocco M; Pikalov A; Goldman R
    Eur Psychiatry; 2021 May; 64(1):e35. PubMed ID: 33966678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.
    Katagiri H; Fujikoshi S; Suzuki T; Fujita K; Sugiyama N; Takahashi M; Gomez JC
    BMC Psychiatry; 2013 Jan; 13():20. PubMed ID: 23311957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
    Harvey PD; Siu CO; Ogasa M; Loebel A
    Schizophr Res; 2015 Aug; 166(1-3):334-8. PubMed ID: 26117157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.
    Loebel AD; Siu CO; Cucchiaro JB; Pikalov AA; Harvey PD
    CNS Spectr; 2014 Apr; 19(2):197-205. PubMed ID: 24330860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
    Ogasa M; Kimura T; Nakamura M; Guarino J
    Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.